Bifogade filer
PDF
Kurs
+3,18%
Likviditet
81,2 MSEK
Kalender
| Tid* | ||
| 2025-10-22 | 07:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-11 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-04-30 | N/A | X-dag ordinarie utdelning ARJO B 0.95 SEK |
| 2025-04-29 | N/A | Årsstämma |
| 2025-04-29 | 07:00 | Kvartalsrapport 2025-Q1 |
| 2025-01-30 | - | Bokslutskommuniké 2024 |
| 2024-10-17 | - | Kvartalsrapport 2024-Q3 |
| 2024-07-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-19 | - | X-dag ordinarie utdelning ARJO B 0.90 SEK |
| 2024-04-18 | - | Årsstämma |
| 2024-04-18 | - | Kvartalsrapport 2024-Q1 |
| 2024-01-30 | - | Bokslutskommuniké 2023 |
| 2023-10-19 | - | Kvartalsrapport 2023-Q3 |
| 2023-07-13 | - | Kvartalsrapport 2023-Q2 |
| 2023-07-12 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-21 | - | X-dag ordinarie utdelning ARJO B 0.85 SEK |
| 2023-04-20 | - | Årsstämma |
| 2023-04-20 | - | Kvartalsrapport 2023-Q1 |
| 2023-01-25 | - | Bokslutskommuniké 2022 |
| 2022-10-28 | - | Kvartalsrapport 2022-Q3 |
| 2022-07-14 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-25 | - | X-dag ordinarie utdelning ARJO B 1.15 SEK |
| 2022-04-22 | - | Årsstämma |
| 2022-04-22 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-03 | - | Bokslutskommuniké 2021 |
| 2021-10-28 | - | Kvartalsrapport 2021-Q3 |
| 2021-07-15 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-28 | - | X-dag ordinarie utdelning ARJO B 0.85 SEK |
| 2021-04-27 | - | Årsstämma |
| 2021-04-27 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-03 | - | Bokslutskommuniké 2020 |
| 2020-10-28 | - | Kvartalsrapport 2020-Q3 |
| 2020-07-17 | - | Kvartalsrapport 2020-Q2 |
| 2020-06-30 | - | X-dag ordinarie utdelning ARJO B 0.65 SEK |
| 2020-06-29 | - | Årsstämma |
| 2020-04-27 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-04 | - | Bokslutskommuniké 2019 |
| 2019-10-22 | - | Kvartalsrapport 2019-Q3 |
| 2019-07-18 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-08 | - | X-dag ordinarie utdelning ARJO B 0.55 SEK |
| 2019-05-07 | - | Årsstämma |
| 2019-05-07 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-04 | - | Bokslutskommuniké 2018 |
| 2018-10-22 | - | Kvartalsrapport 2018-Q3 |
| 2018-07-19 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-07 | - | X-dag ordinarie utdelning ARJO B 0.50 SEK |
| 2018-05-04 | - | Årsstämma |
| 2018-05-04 | - | Kvartalsrapport 2018-Q1 |
| 2018-01-29 | - | Bokslutskommuniké 2017 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
In light of this morning's communication that Joacim Lindoff is leaving his position as CEO of Arjo and to avoid speculation, Arjo is releasing a summary of the year-end report for 2024 before the publication of the complete year-end report on January 30.
Summary of Q4 2024:
- Arjo's net sales increased to 2 989 MSEK (2 879), corresponding to an organic net sales growth of 3.1 percent.
- Adjusted EBITDA amounted to 653 MSEK (614).
- Adjusted EBIT grew 9.7 percent to 375 MSEK (342).
"We are delivering a strong fourth quarter with continued organic growth and profitability improvement, and look forward to presenting more details when the report is published on January 30," says Niclas Sjöswärd, Acting CEO.
No further information will be provided until Arjo publishes the year-end report for 2024 on January 30 at 07:00 CET. The invitation to the conference call will be announced separately.
Note that the summary of the fourth quarter of 2024 has not been reviewed by the company's auditors.
For more information, please contact:
Maria Nilsson, EVP Communications & Public Relations
+46 734 244 515
maria.nilsson@arjo.com
This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:55 CET on January 14, 2025.
About Arjo
At Arjo, we are convinced that good conditions for mobility in healthcare environments are a central part of offering high-quality care. Our products and solutions for patient transfer, hygiene, disinfection, diagnostics, treatment of leg ulcers, prevention of pressure ulcers and venous thrombosis, as well as our healthcare beds, are designed to promote mobility, safety and dignity in all healthcare situations. With over 65 years of experience in improving everyday life for patients and caregivers, and a global team of over 6,500 people, we are constantly working to create better outcomes for people facing mobility challenges. www.arjo.com